Novo Nordisk GLP-1 drug meets goals of MASH trial

The latest stories trending on MedCity News.

Editor's Pick

Top Story Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings Novo Nordisk's Wegovy achieved statistically significant improvement in a Phase 3 study in the fatty liver disease MASH. Based on these preliminary results, the company plans to seek U.S. and European Union approvals in this indication in 2025.

Featured News

The Sewing Machine Changed American Industry Forever — Ambient Listening Tools Could Have a Similar Effect in Healthcare The ability to reduce physician burnout is one of the most exciting things about AI, said CHAI CEO Brian Anderson. In his view, ambient listening AI could end up changing the healthcare delivery world in a similar way that the advent of the sewing machine changed the textile and fashion industry in the 1840s. GoodRx Expands Women's Health Options with New Birth Control and Menopause Offerings GoodRx announced a new e-commerce solution starting with over-the-counter birth control pill Opill. It also is offering new affordability programs for menopause medications with Pfizer. Create a Winning Playbook for Employee Caregivers Tomorrow's goal scoring companies will go on offense today by giving an assist to their caregiving team members. Innovations Shaping the Future of Kidney Care To improve outcomes further, healthcare providers will need to take bold action to diagnose and manage this kidney disease before it becomes chronic or fatal.

Resources

SPONSORED Telemedicine Software Pricing Guide How do you know if you're spending too much or too little on Telemedicine software? This guide from Software Advice breaks down upfront, subscription and hidden costs, plus answers other questions you've been wondering about. Get Your Free Pricing Guide Now

MedCity News • PO Box 901 • New York, NY unsubscribe